Breaking News Instant updates and real-time market news.

EQT

EQT Corporation

, COST

Costco

$167.07

1.86 (1.13%)

09:40
10/06/17
10/06
09:40
10/06/17
09:40

Unusually active option classes on open October 6th

Unusual total active option classes on open include: WisdomTree India Earnings (EPI), EQT Corporation (EQT), Costco (COST), CBS (CBS), Intercept (ICPT), CenturyLink (CTL), MannKind (MNKD), Barrick Gold (ABX), Wynn Resorts (WYNN), and United States Oil Fund (USO).

EQT

EQT Corporation

COST

Costco

$167.07

1.86 (1.13%)

CBS

CBS

ICPT

Intercept

$72.76

4.03 (5.86%)

CTL

CenturyLink

MNKD

MannKind

$4.96

1.42 (40.11%)

ABX

Barrick Gold

WYNN

Wynn Resorts

$146.96

-0.01 (-0.01%)

USO

United States Oil Fund

  • 19

    Oct

  • 26

    Oct

  • 26

    Oct

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 14

    Nov

EQT EQT Corporation

09/26/17
GHSC
09/26/17
UPGRADE
Target $79
GHSC
Buy
EQT Corporation upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Mike Kelly upgraded EQT Corporation (EQT) to Buy and increased its price target to $79 from $57 to reflect increased confidence in the Rice Energy (RICE) acquisition.
08/03/17
08/03/17
DOWNGRADE
Target $30

Equal Weight
Rice Energy downgraded to Equal Weight at Stephens
As previously reported, Stephens analyst Ben Wyatt downgraded Rice Energy (RICE) to Equal Weight from Overweight, with a $30 price target. The analyst notes that the company reported "strong" Q2 results, and acquired 16.5K net acres in the Marcellus while entering into an agreement to sell 36K Barnett acres and 76 Mmcfepd of production from the Barnett. Since the EQT Corporation (EQT) announcement in June, there has been speculation that the transaction would not close due to Jana's involvement with EQT and its push to dissolve the announced EQT/Rice Energy acquisition, the analyst points out. However, he believes the deal will be completed.
07/14/17
HOWW
07/14/17
UPGRADE
HOWW
Outperform
EQT Corporation upgraded to Outperform at Scotia Howard Weil
07/12/17
JEFF
07/12/17
DOWNGRADE
Target $26
JEFF
Hold
Rice Energy downgraded to Hold from Buy at Jefferies
Jefferies analyst Zach Parham downgraded Rice Energy (RICE) to Hold on expectations the acquisition by EQT Corporation (EQT) will be completed. The analyst keeps a $26 price target for the shares.
COST Costco
$167.07

1.86 (1.13%)

10/06/17
10/06/17
DOWNGRADE
Target $165

Equal Weight
Costco downgraded on EPS growth slowdown at Morgan Stanley
As previously reported, Morgan Stanley analyst Simeon Gutman downgraded Costco to Equal Weight from Overweight, stating that after its Q4 report last night he has cut his FY18 EPS growth estimate to $6.30. Moderating membership growth also led him to lower his EBITDA multiples, said Gutman, who added that the combination of decelerating EPS growth and "membership slippage" may make it tough for the stock to outperform. Gutman lowered his price target to $165 from $190 on Costco shares, which are down 4.5% to $159.50 in pre-market trading following last night's quarterly report.
10/06/17
MSCO
10/06/17
DOWNGRADE
MSCO
Equal Weight
Costco downgraded to Equal Weight from Overweight at Morgan Stanley
10/06/17
RBCM
10/06/17
NO CHANGE
Target $190
RBCM
Outperform
Costco has some of the best traffic growth in retail, says RBC Capital
RBC Capital analyst Scot Ciccarelli said Costco reported better than expected Q4 results as total comps increased 5.7% versus his 5.3% estimate and consensus of 5.1%, while gross margin pressures were largely offset by expense leverage. Despite investors fears regarding risk from e-commerce, the analyst said Costco continues to have some of the best traffic growth in retail and is gaining traction from its own e-commerce initiates. Ciccarelli said he remains a buyer of Costo and increased his price target on shares to $190 from $184 and reiterated his Outperform rating on shares.
10/06/17
BARD
10/06/17
NO CHANGE
Target $200
BARD
Outperform
Any post-earnings pullback in Costco provides a buying opportunity, says Baird
Baird analyst Peter Benedict noted Costco reported better than expected Q4 earnings and said it remains a compelling growth staple idea with its healthy fundamentals and an improved valuation profile. The analyst said any pullback in Costco share would be a good buying opportunity and shares look attractive at current levels. Benedict reiterated his Outperform rating and $200 price target on Costco shares.
CBS CBS

09/13/17
NEED
09/13/17
NO CHANGE
NEED
CBS Internet video channels could be worth $7.2B, says Needham
Needham analyst Laura Martin estimates that CBS' (CBS) Internet video services could generate $1.2B of revenue in 2020. She notes that Netflix's (NFLX) market cap is six times its revenue. If CBS' Internet video services are valued using that multiple, they would be worth $7.2B, or 30% of CBS' current market cap, according to the analyst. She keeps an $80 price target and a Buy rating on the shares.
09/15/17
JPMS
09/15/17
NO CHANGE
Target $75
JPMS
Overweight
CBS recent share weakness overdone, says JPMorgan
JPMorgan analyst Alexia Quadrani views the recent pullback in shares of CBS (CBS) as overdone. The stock has underperformed over the prior month, down 12% versus the S&P 500 Index up 1%, Quadrani tells investors in a research note titled "Weather Channel's Gain is NFL's Pain; CBS Weakness Overdone." The analyst attributes yesterday's selloff to NFL ratings for week one, which declined 12% year-over-year. It is unreasonable to draw conclusions from just one weekend of games, especially last weekend given the storms, the analyst argues. Further, Quadrani says CBS CEO Les Moonves' comment yesterday that Amazon (AMZN) would be interested in bidding for NFL rights when they come due early next decade is "hardly news." She keeps an Overweight rating on CBS with a $75 price target.
09/19/17
09/19/17
NO CHANGE

Cowen lowers price targets on media companies
Cowen analyst Doug Crentz cut his price targets for several media companies, as he believes that the margin pressure on TV networks will continue. The analyst believes that consensus estimates for TV broadcasters are too high, as he expects that the decline in the sector's EBITDA margin will more than double this year, driven by lower ad and affiliate revenue. He believes that two "deep-pocketed, low margin competitors -Netflix (NFLX) and Amazon (AMZN) - are the root of the problem. He cut his price target on Viacom (VIAB) to $31 from $41, on Discovery (DISCA) to $19 from $25, on Fox (FOXA) to $29 from $32, on CBS (CBS) to $69 from $70 and on Disney (DIS) to $94 from $95.
09/05/17
WELS
09/05/17
UPGRADE
Target $116
WELS
Outperform
Disney upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Marci Ryvicker upgraded Disney (DIS) to Outperform and raised her price target for the shares to $116 from $109. The owner of ESPN and ABC closed Friday up 31c to $101.50. Concerns over potential dilution from the BAMTech stake and the streaming apps are "widely overdone," Ryvicker tells investors in a research note where she also downgraded Viacom (VIAB). She expects the TV ecosystem will soon undergo on an accelerated push into over-the-top. As such, investors may need to start increasing exposure to media companies with solid streaming strategies, such as CBS (CBS), 21st Century Fox (FOXA), and Disney, and lessen exposure to those that do not, such as Viacom and Scripps Networks (SNI)/Discovery Communications (DISCA), Ryvicker argues. The analyst likes the current entry point for Disney shares.
ICPT Intercept
$72.76

4.03 (5.86%)

10/02/17
RBCM
10/02/17
NO CHANGE
RBCM
Enanta data positive, says RBC Capital
RBC Capital analyst Brian Abrahams says that preclinical data on Enanta's (ENTA) EDP-305 presented at the AASLD conference "shows comparable-to-better effects on fibrosis to other anti-fibrotic agents." The analyst says that although the test was done on rats, other anti-fibrotic agents' impact on fibrosis in rats has been similar to their impact on fibrosis in humans. The analyst adds that the data indicates that EDP-305 may have a more beneficial effect on cholesterol genes than Intercept's (ICPT) Ocaliva drug. The analyst predicts that Phase I data on Enanta's drug, expected to be presented at the end of the conference, to be positive and potentially cause the shares to rise. He keeps an Outperform rating on Enata.
10/04/17
JMPS
10/04/17
DOWNGRADE
JMPS
Market Perform
Intercept downgraded to Market Perform from Outperform at JMP Securities
10/04/17
10/04/17
DOWNGRADE

Market Perform
Intercept downgraded on reduced NASH expectations at JMP Securities
As previously reported, JMP Securities analyst Liisa Bayko downgraded Intercept to Market Perform from Outperform after she adjusted her assumptions for market penetration of Ocaliva in NASH given the rapidly evolving competitive landscape and cases of serious liver injury and deaths reported in Ocaliva-treated PBC patients. The analyst, who has removed cirrhotic patients from her NASH model to be conservative, now believes Intercept is fairly valued at current levels.
10/06/17
GHSC
10/06/17
INITIATION
Target $136
GHSC
Buy
Intercept initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Intercept with a Buy and $136 price target. The analyst expects Q4 prescription trends will support growing confidence that the FDA's statement has not had a longterm effect on Ocaliva Rx behavior in its approved use in patients with primary biliary cholangitis.
CTL CenturyLink

10/04/17
LEHM
10/04/17
NO CHANGE
Target $19
LEHM
Underweight
Barclays lowers price targets for CenturyLink, Level 3
Barclays analyst Amir Rozwadowski lowered his price target for Underweight-rated CenturyLink (CTL) to $19 from $23 and for Equal Weight-rated Level 3 Communications (LVLT) to $53 from $59. The combination of downward estimate revisions, management changes and a delay in the timing of merger close has heightened the perceived challenges facing the joint entity, Rozwadowski tells investors in a research note. The analyst, however, sees less downside potential for CenturyLink based on his new price target. He believes improved clarity on the joint entity's strategic priorities as well as the size and scope of synergy upside would "serve as a net benefit for helping the company recapture the narrative and provide a necessary realignment of investor expectations."
09/28/17
RAJA
09/28/17
NO CHANGE
RAJA
DOJ appointment catalyst for CenturyLink, Level 3 deal, says Raymond James
Makan Delrahim was finally confirmed by the Senate yesterday as head of the Department of Justice Antitrust Division, Raymond James analyst Frank Louthan tells investors in a research note. He believes not having an antitrust head is at least partially to blame for the delay in mergers and acquisitions in the Technology & Communications space this year, including outstanding transactions like CenturyLink (CTL)/Level 3 Communications (LVLT) and AT&T (T)/Time Warner (TWX), as well as potential deals like Sprint (S)/T-Mobile U.S. (TMUS). The appointment of Delrahim is a catalyst for the approval of CenturyLink's acquisition of Level 3, where the Department of Justice has been the bottleneck, Louthan writes.
08/23/17
MSCO
08/23/17
NO CHANGE
Target $26
MSCO
Overweight
CenturyLink, Uniti Group risk/reward attractive, says Morgan Stanley
Morgan Stanley analyst Simon Flannery is surprised by the magnitude of share declines for Overweight rated CenturyLink (CTL) and Uniti Group (UNIT) and continues to view risk/reward as attractive. Flannery said Q2 results showed cable continued to to drive consumer sub growth, reinforcing his view to own these two infrastructure assets that will benefit from growing business IP/mobile traffic. The analyst trimmed CenturyLink's price target to $26 from $27 and cut Uniti's to $24 from $32.
08/18/17
BOFA
08/18/17
NO CHANGE
Target $42
BOFA
Buy
CenturyLink and Level 3 deal moving forward, says BofA/Merrill
BofA/Merrill analyst David Barden said weakness in CenturyLink (CTL) appears related to reports that the regulatory timeline for the Level 3 (LVLT) merger could slip past the September 30 target date. Barden said Department of Justice timing remains on track but The California Public Utility Commission has a 60 day window to approve the deal. After 60 days, there is a potential lag of 30 days which would put the final approval timing in the first week of November, at the latest. Barden said a 5 week slippage is possible, but no delay is certain, and the regulatory time frame has zero bearing on the deal approval. Further, the analyst said some investors view Windstream's (WIN) surprise dividend cut as an indicator that CenturyLink may do the same post the Level 3 deal. Barden does not expect a cut and notes the company is not in the same position as Winstream and management stated it continues to pay its $2.16/share annual dividend and that the Level 3 acquisition improves the payout ratio. The analyst rates CenturyLink a Buy with a $42 price target.
MNKD MannKind
$4.96

1.42 (40.11%)

10/03/17
MAXM
10/03/17
NO CHANGE
MAXM
Label revision should drive MannKind sales, says Maxim
Maxim analyst Jason Kolbert says that the new label on MannKind's Afrezza drug, which includes information about its speed of delivery, "should help drive adoption" of the drug, He keeps a $4 price target and a Buy rating on the shares.
10/02/17
MAXM
10/02/17
NO CHANGE
MAXM
MannKind still well-positioned to grow, says Maxim
Maxim analyst Jason Kolbert does not expect MannKind to declare bankruptcy because he does not believe that the company's main debtholders want to see that outcome, and because he thinks that its debt "can be managed." He says that over the longer term, revenue from the company's Afrezza product can enable it to overcome its debt. Kolbert keeps a $4 price target and a Buy rating on the shares.,
08/11/17
08/11/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Strongbridge Biopharma (SBBP) initiated with an Outperform at Oppenheimer. 2. Discovery (DISCA) initiated with a Neutral at Piper Jaffray. 3. MannKind (MNKD) initiated with a Buy at Maxim. 4. Veritone (VERI) initiated with a Buy at Roth Capital. 5. Esperion (ESPR) initiated with a Neutral at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/11/17
MAXM
08/11/17
INITIATION
Target $4
MAXM
Buy
MannKind initiated with a Buy at Maxim
Maxim analyst Jason Kolbert started MannKind with a Buy rating and $4 price target, stating that the relaunch of Afrezza is building traction. A "conservative" 5% share of the U.S. insulin market is a $350M opportunity for Afrezza, added Kolbert.
ABX Barrick Gold

06/29/17
BREN
06/29/17
UPGRADE
BREN
Hold
Barrick Gold upgraded to Hold from Sell at Berenberg
06/29/17
BMOC
06/29/17
NO CHANGE
BMOC
Barrick Gold new digital strategy making a difference, says BMO Capital
BMO Capital analyst Andrew Kaip says that Barrick is "leading the industry..in digitization and data analytics." The analyst says that the company is beginning to see the returns from its new strategy, with the company's digital transformation hub, Codemine "delivering early results." Kaip thinks that the new strategy will deliver "some wins" for Barrick, He trimmed his price target on the stock to $21 from $24 but keeps an Outperform rating.
07/06/17
BMOC
07/06/17
DOWNGRADE
BMOC
Market Perform
Barrick Gold downgraded to Market Perform from Outperform at BMO Capital
03/16/17
RBCM
03/16/17
UPGRADE
RBCM
Outperform
Barrick Gold upgraded on improved outlook, valuation at RBC Capital
As noted earlier, RBC Capital upgraded Barrick Gold to Outperform from Sector Perform. Analyst Stephen Walker upgraded the stock based on his improved production and cost outlook for the company, as well as valuation. Target to $23 from $19.
WYNN Wynn Resorts
$146.96

-0.01 (-0.01%)

07/26/17
07/26/17
DOWNGRADE

Market Perform
Update: Wynn Resorts downgraded to Market Perform at Telsey Advisory
As previously reported, Telsey Advisory downgraded Wynn Resorts to Market Perform from Outperform and maintained a $150 price target. Analyst David Katz said the execution of the Palace opening has not been what he expected and believes the Macau market is facing increasingly challenging comps starting in Q3 and beyond. Katz ultimately believes the Palace will achieve its objectives and the overall Wynn thesis remains intact, but views visibility as limited over the next several quarters.
07/26/17
07/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Market Perform from Outperform at BMO Capital. 2. Zoetis (ZTS) downgraded to Hold from Buy at Deutsche Bank with analyst Gregg Gilbert saying the risk/reward is more balanced with the shares up 18% year-to-date. 3. CF Industries (CF) downgraded to Neutral from Outperform at Credit Suisse with analyst Christopher Parkinson citing the recent rally in shares. 4. Eli Lilly (LLY) downgraded to Market Perform from Outperform at Leerink with analyst Seamus Fernandez saying that the regulatory update for Olumiant removes upside optionality in rheumatoid arthritis and possibly other indications given concerns over thrombosis risk. 5. Wynn Resorts (WYNN) was downgraded to Hold from Buy at Union Gaming and to Market Perform from Outperform at Telsey Advisory. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/15/17
DBAB
08/15/17
UPGRADE
Target $150
DBAB
Buy
Wynn Resorts upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Carlo Santarelli upgraded Wynn Resorts to Buy and raised his price target for the shares to $150 from $138. The analyst believes the mass ramp at Wynn Palace is beginning to accelerate and that current share levels represent a favorable entry point.
09/29/17
UBSW
09/29/17
NO CHANGE
Target $174
UBSW
Buy
Wynn Resorts price target raised to $174 from $149 at UBS
UBS analyst Robin Farley raised her price target on Wynn Resorts to $174 from $149 to reflect higher Q4 GGR growth expectations for Macau. The higher GGR estimates are driven by a strong Golden Week, pent-up demand from typhoons, and a stronger RMB, which positions Macau more favorably for mass visitors. Farley reiterated her Buy rating on Wynn Resorts shares.
USO United States Oil Fund

TODAY'S FREE FLY STORIES

03:45
10/20/17
10/20
03:45
10/20/17
03:45
General news
FX Action: USD-CAD has rallied back above 1.2500 »

FX Action: USD-CAD has…

02:55
10/20/17
10/20
02:55
10/20/17
02:55
General news
FX Update: The dollar has rallied across the board »

FX Update: The dollar…

01:45
10/20/17
10/20
01:45
10/20/17
01:45
General news
Breaking General news story  »

Federal Reserve Chair…

STLD

Steel Dynamics

$37.78

1.34 (3.68%)

21:35
10/19/17
10/19
21:35
10/19/17
21:35
Upgrade
Steel Dynamics rating change at KeyBanc »

Steel Dynamics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

RXDX

Ignyta

$16.65

0.4 (2.46%)

20:30
10/19/17
10/19
20:30
10/19/17
20:30
Syndicate
Ignyta 10M share Secondary priced at $16.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 20

    Oct

PG

Procter & Gamble

$91.59

-0.4904 (-0.53%)

, GE

General Electric

$23.58

0.46 (1.99%)

20:25
10/19/17
10/19
20:25
10/19/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$91.59

-0.4904 (-0.53%)

GE

General Electric

$23.58

0.46 (1.99%)

HON

Honeywell

$143.62

0.18 (0.13%)

SLB

Schlumberger

$64.50

-1.41 (-2.14%)

STI

SunTrust

$59.11

-0.18 (-0.30%)

SYF

Synchrony

$31.71

0.2 (0.63%)

CFG

Citizens Financial

$37.43

0.25 (0.67%)

KSU

Kansas City Southern

$103.78

0.97 (0.94%)

GNTX

Gentex

$20.66

0.2 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 02

    Nov

WILC

G. Willi-Food

$5.85

-0.14 (-2.34%)

18:35
10/19/17
10/19
18:35
10/19/17
18:35
Hot Stocks
G. Willi-Food receives notice from Arla Food ending distribution agreement »

G. Willi-Food's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$71.26

-0.46 (-0.64%)

18:30
10/19/17
10/19
18:30
10/19/17
18:30
Hot Stocks
Macquarie Infrastructure CEO to become CEO of Macquarie Atlas Roads in 2018 »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

BIDU

Baidu

$264.52

-4.45 (-1.65%)

18:30
10/19/17
10/19
18:30
10/19/17
18:30
Hot Stocks
Baidu collaborating with China's BAIC Group and King Long for autonomous driving »

Baidu signed strategic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

IBKC

Iberiabank

$80.15

0.05 (0.06%)

18:27
10/19/17
10/19
18:27
10/19/17
18:27
Hot Stocks
IBERIABANK to acquire Gibraltar Private Bank & Trust »

IBERIABANK Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

VBTX

Veritex

$27.04

-0.02 (-0.07%)

18:20
10/19/17
10/19
18:20
10/19/17
18:20
Hot Stocks
Veritex receives regulatory approval for Liberty Bancshares merger »

Veritex Holdings, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BHP

BHP Billiton

$41.56

0.06 (0.14%)

18:03
10/19/17
10/19
18:03
10/19/17
18:03
Hot Stocks
BHP Billiton CEO sees challenges around geopolitical uncertainty remaining »

In annual shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRRX

Durect

$1.97

0.03 (1.55%)

17:59
10/19/17
10/19
17:59
10/19/17
17:59
Hot Stocks
Durect: Phase 3 clinical trial for POSIMIR did not meet primary endpoint »

Durect reported that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTNP

Titan Pharmaceuticals

$1.90

-0.1 (-5.00%)

17:49
10/19/17
10/19
17:49
10/19/17
17:49
Hot Stocks
Titan Pharmaceuticals presents non-clinical data from liothyronine implant »

Titan Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSA

MSA Safety

$82.20

1.37 (1.69%)

17:46
10/19/17
10/19
17:46
10/19/17
17:46
Earnings
MSA Safety reports Q3 EPS 92c, consensus 80c »

Reports Q3 revenue $296M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

SKX

Skechers

$24.03

-1.06 (-4.22%)

, CAI

CAI International

$31.38

-0.05 (-0.16%)

17:41
10/19/17
10/19
17:41
10/19/17
17:41
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

SKX

Skechers

$24.03

-1.06 (-4.22%)

CAI

CAI International

$31.38

-0.05 (-0.16%)

PYPL

PayPal

$67.25

-0.01 (-0.01%)

MXIM

Maxim Integrated

$50.09

0.24 (0.48%)

IMDZ

Immune Design

$5.50

-1.05 (-16.03%)

NCR

NCR Corp.

$37.05

-0.26 (-0.70%)

TACO

Del Taco

$15.39

-0.01 (-0.06%)

ATHN

athenahealth

$116.41

-4.37 (-3.62%)

ISRG

Intuitive Surgical

$357.46

3.09 (0.87%)

ETFC

E-Trade

$43.69

-0.23 (-0.52%)

CELG

Celgene

$135.96

-1.21 (-0.88%)

PBMD

Prima BioMed

$2.36

-0.02 (-0.84%)

AAXN

Axon

$24.62

-0.37 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 21

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 29

    Nov

DGX

Quest Diagnostics

$93.23

1.18 (1.28%)

17:37
10/19/17
10/19
17:37
10/19/17
17:37
Hot Stocks
Quest Diagnostics acquires Cleveland HeartLab, terms not disclosed »

Advantage Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

AAXN

Axon

$24.62

-0.37 (-1.48%)

17:34
10/19/17
10/19
17:34
10/19/17
17:34
Hot Stocks
Axon says now aware of comment letter over SEC's review of 10-K, 10-Q »

Axon Enterprise said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMX

BioPharmX

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on BioPharmX »

BioPharmX files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBVX

MabVax Therapeutics

$0.74

0.0248 (3.47%)

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on MabVax Therapeutics »

MabVax Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKC

Iberiabank

$80.15

0.05 (0.06%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Earnings
Iberiabank reports Q3 non-GAAP EPS $1.00, consensus $1.16 »

Reports Q3 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

DRRX

Durect

$1.97

0.03 (1.55%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Hot Stocks
Breaking Hot Stocks news story on Durect »

Durect trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCP

Quality Care Properties

$16.26

0.07 (0.43%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Quality Care Properties provides update on HCR ManorCare »

Quality Care Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTR

Frontier Communications

$11.48

0.02 (0.17%)

, CHH

Choice Hotels

$68.45

0.25 (0.37%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Frontier Communications named a Qualified Vendor with Choice Hotels Internationa »

Frontier Communications…

FTR

Frontier Communications

$11.48

0.02 (0.17%)

CHH

Choice Hotels

$68.45

0.25 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 08

    Nov

DRIO

DarioHealth

$1.98

-0.2 (-9.17%)

17:16
10/19/17
10/19
17:16
10/19/17
17:16
Syndicate
Breaking Syndicate news story on DarioHealth  »

DarioHealth files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.